IP Library Granted Patent US 11,090,460
Granted Patent B2
US 11,090,460 · App. 16/219,738 · Granted Aug 17, 2021

Method for infusing an immunotherapy agent to a solid tumor for treatment

Inventors: David Benjamin Jaroch (Arvada, CO); James E. Chomas (Denver, CO)
Assignee: Surefire Medical, Inc.
A61M25/0029A61L29/041A61L29/06A61L29/08A61L29/085A61L29/145A61L29/16A61M25/04A61M25/10A61L2300/426A61L2300/608A61L2400/10A61L2420/02A61L2420/08A61M2025/0004A61M2025/0042A61M2025/0047A61M2025/105A61M2025/1052A61M2202/0007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,090,460
App. No.
16/219,738
Granted
Aug 17, 2021
Kind
B2
Abstract

A method for delivering an immunotherapy agent to a tumor includes advancing the delivery device into a vessel of a patient, and infusing the agent under pressure into the vessel to penetrate the tumor. The delivery device prevents reflux of the agent toward non-treatment sites.

Claims (12)

1. A method of delivering an immunotherapy agent through a target vessel in communication with a tumor, the vessel having an initial intravascular pressure, the method comprising:

a) providing an immunotherapy delivery device including a flexible catheter having a proximal end and a distal end, an expandable fluid pressure modulating structure fixed adjacent the distal end of the catheter, an agent delivery lumen extending through the catheter and opening to an orifice at a distal tip of the catheter;

b) providing an immunotherapy agent;

c) inserting said device into the target vessel;

d) using the expandable fluid pressure modulating structure to modulate the pressure in the target vessel relative to the initial intravascular pressure; and then

e) infusing the immunotherapy agent through the lumen and out of the orifice of the catheter.

2. The method of claim 1 , wherein:

the pressure in the vessel is modulated to reduce the pressure in the vessel relative to the initial intravascular pressure prior to infusing.

3. The method of claim 1 , wherein:

the immunotherapy agent is infused at a pressure different than the initial intravascular pressure.

4. The method of claim 1 , further comprising:

while infusing, preventing reflux of the immunotherapy agent into non-target vessels.

Assignments (3)
SECURITY INTEREST Recorded Apr 30, 2024
From: TRISALUS LIFE SCIENCES, INC.
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP
Reel/Frame 067274/0733 →
CHANGE OF NAME Recorded Sep 30, 2021
From: SUREFIRE MEDICAL, INC.
To: TRISALUS LIFE SCIENCES, INC.
Reel/Frame 057693/0506 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2018
From: JAROCH, DAVID BENJAMIN; CHOMAS, JAMES E.
To: SUREFIRE MEDICAL, INC.
Reel/Frame 047793/0599 →
Continuity (3)
Division 15064158 · Mar 8, 2016
Provisional Application 62140651 · Mar 31, 2015
Related Publication 20190111234A1 · Apr 18, 2019
Cited By (9)
US 12,186,182 US 12,369,932 US 12,377,245 US 12,414,774 US 12,433,597 US 12,502,479 US 12,661,486 US 12,667,693 US 12,690,870